Welcome to PKU Meetings

This website has been funded and developed by BioMarin International Ltd. as a scientific and educational resource for healthcare professionals in EMEA region interested to learn more about phenylketonuria (PKU), its current clinical care and management along with the latest PKU research findings.

This website contains promotional information on BioMarin products, which is displayed based on the prescribing information approved by the European Medicines Agency – EMA. Prescribing information for KUVAN® and PALYNZIQ®▼ can be accessed here, and within PKU Meetings.

Log in Register

Are you a healthcare professional?

The information provided on this website is intended for use by healthcare professionals practicing in the Europe, Middle East and Africa – EMEA region. The dissemination of this information may be subject to different medical and regulatory requirements across the EMEA countries.

This website may contain promotional information on BioMarin products, which is displayed based on the prescribing information approved by the European Medicines Agency – EMA.

I confirm that I am a healthcare professional practicing in EMEA region I am a member of the general public

All the content about KUVAN® (sapropterin dihydrochloride) and PALYNZIQ®▼ (pegvaliase) injection currently available on PKU Meetings platform has been approved and is consistent with the latest and most updated version of EU SmPC.

Content on PKU Meetings is periodically reviewed by BioMarin and may be subject to changes to assure compliance with EMEA general regulations around promotion of prescription medicines.

You can always find out the most updated version of both KUVAN® (sapropterin dihydrochloride) and PALYNZIQ® (pegvaliase) injection's abbreviated prescribing information (API) under the menu option "API" at the top bar navigation.

Close

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.